Report Detail

Pharmaceuticals & Healthcare Nabriva Therapeutics plc (NBRV) - Financial and Strategic SWOT Analysis Review

  • RnM2190075
  • |
  • 14 June, 2019
  • |
  • Global
  • |
  • 25 pages
  • |
  • GlobalData
  • |
  • Pharmaceuticals & Healthcare

Nabriva Therapeutics plc (NBRV) - Financial and Strategic SWOT Analysis Review

Table of Contents

    Section 1 - About the Company

      Nabriva Therapeutics plc - Key Information

        Nabriva Therapeutics plc - Overview

          Nabriva Therapeutics plc - Key Employees

            Nabriva Therapeutics plc - Key Employee Biographies

              Nabriva Therapeutics plc - Key Operational Heads

                Nabriva Therapeutics plc - Major Products and Services

                  Nabriva Therapeutics plc - History

                    Nabriva Therapeutics plc - Company Statement

                      Nabriva Therapeutics plc - Locations And Subsidiaries

                        Nabriva Therapeutics plc - Key Manufacturing facilities

                          Head Office

                            Other Locations & Subsidiaries

                              Section 2 - Company Analysis

                                Nabriva Therapeutics plc - Business Description

                                  Nabriva Therapeutics plc - Corporate Strategy

                                    Nabriva Therapeutics plc - SWOT Analysis

                                      SWOT Analysis - Overview

                                        Nabriva Therapeutics plc - Strengths

                                          Nabriva Therapeutics plc - Weaknesses

                                            Nabriva Therapeutics plc - Opportunities

                                              Nabriva Therapeutics plc - Threats

                                                Nabriva Therapeutics plc - Key Competitors

                                                  Section 3 - Company Financial Performance Charts

                                                    Nabriva Therapeutics plc - Financial Ratios

                                                      Financial Ratios - Capital Market Ratios

                                                        Financial Ratios - Annual Ratios

                                                          Financial Ratios - Interim Ratios

                                                            Financial Ratios - Ratio Charts

                                                              Section 4 - Appendix



                                                                    Ratio Definitions

                                                                      About GlobalData

                                                                        Contact Us


                                                                            Note*: Some sections may be missing if data is unavailable for the company


                                                                            Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company’s product candidate includes lefamulin, a pleuromutilin antibiotic, being developed in both intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia. Its other pipeline products comprise BC-7013 for the topical treatment of a variety of gram-positive infections including uncomplicated skin and skin structure infections; and Contepo to treat urinary tract infections. It partners with pharmaceutical and biotechnology companies. It has operational presence in Austria and the US. Nabriva is headquartered in Dublin, Ireland.

                                                                            Nabriva Therapeutics Plc Key Recent Developments

                                                                            May 22,2019: Nabriva Therapeutics to Present at the Jefferies 2019 Healthcare Conference
                                                                            May 10,2019: Nabriva Therapeutics reports first quarter 2019 financial results and recent corporate highlights
                                                                            Apr 30,2019: Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous CONTEPO (fosfomycin) for injection
                                                                            Mar 12,2019: Nabriva Therapeutics reports 2018 financial results and recent corporate highlights
                                                                            Nov 20,2018: Nabriva Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

                                                                            This comprehensive SWOT profile of Nabriva Therapeutics Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

                                                                            This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Nabriva Therapeutics Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

                                                                            The profile contains critical company information including*,

                                                                            - Business description – A detailed description of the company’s operations and business divisions.
                                                                            - Corporate strategy – Analyst’s summarization of the company’s business strategy.
                                                                            - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
                                                                            - Company history – Progression of key events associated with the company.
                                                                            - Major products and services – A list of major products, services and brands of the company.
                                                                            - Key competitors – A list of key competitors to the company.
                                                                            - Key employees – A list of the key executives of the company.
                                                                            - Executive biographies – A brief summary of the executives’ employment history.
                                                                            - Key operational heads – A list of personnel heading key departments/functions.
                                                                            - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
                                                                            - Key manufacturing facilities – A list of key manufacturing facilities of the company.
                                                                            - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
                                                                            - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

                                                                            Note*: Some sections may be missing if data is unavailable for the company.

                                                                            Key benefits of buying this profile include,

                                                                            You get detailed information about the company and its operations to identify potential customers and suppliers.
                                                                            - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

                                                                            Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
                                                                            - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

                                                                            Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
                                                                            - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

                                                                            Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
                                                                            - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

                                                                            Gain key insights into the company for academic or business research.
                                                                            - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

                                                                            Get latest Market Research Reports on Nabriva Therapeutics plc (NBRV) . Industry analysis & Market Report on Nabriva Therapeutics plc (NBRV) is a syndicated market report, published as Nabriva Therapeutics plc (NBRV) - Financial and Strategic SWOT Analysis Review. It is complete Research Study and Industry Analysis of Nabriva Therapeutics plc (NBRV) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                            REPORT YOU MIGHT BE INTERESTED

                                                                            Purchase this Report

                                                                            Credit card Logo

                                                                            Related Reports

                                                                            Reason to Buy

                                                                            Request for Sample of this report